Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Fuji Pharma to File Biosimilars for Japan Approval by 2021: President
Fuji Pharma expects that some of the investigational biosimilars currently under development by its Icelandic partner will be filed in Japan by 2021, President Eiji Takemasa, explained at an earnings briefing on May 17. Fuji Pharma has concluded a collaboration…
To read the full story
Related Article
- Fuji Pharma In-Licenses Sixth Biosimilar from Alvotech
February 25, 2022
- Fuji Pharma Invests US$50 Million in Alvotech to Boost Biosimilar Business in Japan
December 21, 2018
BUSINESS
- FDA Approves Takeda’s PV Drug Mimrylo
September 1, 2026
- Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure
August 31, 2026
- Sumitomo Pharma Goes Global with Adjuvants, Targets 100 Billion Yen
August 31, 2026
- Shionogi to Get US$36.9 Million as US Govt Procures Fetroja
August 31, 2026
- Daiichi’s CD25-Directed ADC DS1025 Enters Clinic
August 31, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…